...
首页> 外文期刊>American journal of clinical pathology. >PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin.
【24h】

PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin.

机译:PAX-2在原发性肾肿瘤的诊断中:与肾细胞癌标志物抗原和肾特异性钙黏附蛋白的免疫组化比较。

获取原文
获取原文并翻译 | 示例
           

摘要

The diagnosis of renal cell carcinoma (RCC) remains problematic, especially in the context of metastasis or small needle biopsy specimens. The renal cell carcinoma marker (RCCM) and kidney-specific cadherin (KSC) are considered specific markers for RCC but are expressed preferentially in specific subtypes of RCC of lower grades. This study was aimed at evaluating the usefulness of PAX-2 in the diagnosis of renal tumors and comparing it with that of RCCM and KSC. Immunostaining for PAX-2, RCCM, and KSC was performed on consecutive tissue sections of 130 renal tumors. PAX-2 was successfully detected in routine tissue specimens. Although PAX-2 seems to be more sensitive than RCCM and KSC, there is significant staining overlap in relation to histologic subtypes, justifying the use of all 3 markers, which helps detect the vast majority of renal neoplasms. PAX-2 seems to have a significant role in renal neogenesis and may represent a novel therapeutic target.
机译:肾细胞癌(RCC)的诊断仍然存在问题,尤其是在转移或小针头活检标本的情况下。肾细胞癌标志物(RCCM)和肾特异性钙粘蛋白(KSC)被认为是RCC的特异性标志物,但优先在较低等级的RCC的特定亚型中表达。这项研究旨在评估PAX-2在肾肿瘤诊断中的有用性,并将其与RCCM和KSC进行比较。对130例肾肿瘤的连续组织切片进行了PAX-2,RCCM和KSC的免疫染色。在常规组织标本中成功检测到PAX-2。尽管PAX-2似乎比RCCM和KSC更敏感,但在组织学亚型方面存在明显的染色重叠,证明所有3种标记物的使用都是合理的,这有助于检测绝大多数肾脏肿瘤。 PAX-2似乎在肾新生中具有重要作用,并且可能代表一种新的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号